InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV) The Company is assessing the most efficient ...
Myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis is a systemic condition affecting the small vessels with production of MPO-ANCA in serum. It has been suggested ...
Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Practical, individualized care for patients with antineutrophil cytoplasmic antibody-associated ...
ST. GALLEN, Switzerland & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ:CCXI) today announced positive ...
-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- “The vasculitis community is elated that TAVNEOS is now approved, bringing a much-needed new treatment option to ...
A data-driven subclassification of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis has identified five distinct clusters with varying degrees of kidney involvement and systemic ...
Wegener's granulomatosis, microscopic polyangiitis (MPA), Churg–Strauss syndrome, and primary pauci-immune crescentic glomerulonephritis are associated with circulating anti-neutrophil cytoplasmic ...
Researchers in Japan showed that a unique neutrophil subset, characterized by type II interferon signature genes (T2ISG), along with elevated levels of interferon gamma in the blood, can predict the ...
Please provide your email address to receive an email when new articles are posted on . The findings apply specifically to patients with ANCA-associated vasculitis without severe glomerulonephritis or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results